撒哈拉以南非洲地区耐多药结核病流行趋势：系统评价与荟萃分析
Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis.
作者信息
Musa Baba Maiyaki, Adamu Aishatu L, Galadanci Najibah A, Zubayr Bashir, Odoh Chisom N, Aliyu Muktar H
机构信息
Department of Medicine, Bayero University, Kano, Nigeria.
Department of Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria.
出版信息
PLoS One. 2017 Sep 25;12(9):e0185105. doi: 10.1371/journal.pone.0185105. eCollection 2017.
Abstract
BACKGROUND
Multidrug resistant tuberculosis (MDR-TB), is an emerging public health problem in sub-Saharan Africa (SSA). This study aims to determine the trends in prevalence of MDR-TB among new TB cases in sub-Saharan Africa over two decades.
METHODS
We searched electronic data bases and accessed all prevalence studies of MDR-TB within SSA between 2007 and 2017. We determined pooled prevalence estimates using random effects models and determined trends using meta-regression.
RESULTS
Results: We identified 915 studies satisfying inclusion criteria. Cumulatively, studies reported on MDR-TB culture of 34,652 persons. The pooled prevalence of MDR-TB in new cases was 2.1% (95% CI; 1.7-2.5%). There was a non-significant decline in prevalence by 0.12% per year.
CONCLUSION
We found a low prevalence estimate of MDR-TB, and a slight temporal decline over the study period. There is a need for continuous MDR-TB surveillance among patients with TB.
摘要
背景
耐多药结核病（MDR-TB）是撒哈拉以南非洲（SSA）一个新出现的公共卫生问题。本研究旨在确定二十多年来撒哈拉以南非洲新结核病病例中耐多药结核病的流行趋势。
方法
我们检索了电子数据库，并获取了2007年至2017年期间撒哈拉以南非洲地区所有耐多药结核病的患病率研究。我们使用随机效应模型确定合并患病率估计值，并使用元回归确定趋势。
结果
我们确定了915项符合纳入标准的研究。累计有34652人的耐多药结核病培养结果被报道。新病例中耐多药结核病的合并患病率为2.1%（95%CI；1.7-2.5%）。患病率每年下降0.12%，差异无统计学意义。
结论
我们发现耐多药结核病的患病率估计值较低，且在研究期间略有下降。有必要对结核病患者进行持续的耐多药结核病监测。
相似文献
1
Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis.
PLoS One. 2017 Sep 25;12(9):e0185105. doi: 10.1371/journal.pone.0185105. eCollection 2017.
2
Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
BMC Infect Dis. 2017 Mar 20;17(1):219. doi: 10.1186/s12879-017-2323-y.
3
Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis.
BMC Public Health. 2017 Oct 17;17(1):817. doi: 10.1186/s12889-017-4779-5.
4
Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: a systematic review and spatio-temporal analysis.
BMC Infect Dis. 2017 Jan 10;17(1):57. doi: 10.1186/s12879-016-2151-5.
5
Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies.
Infect Dis Poverty. 2017 Jan 17;6(1):7. doi: 10.1186/s40249-016-0214-x.
6
A systematic review of adrenal insufficiency among patients with pulmonary tuberculosis in Sub-Saharan Africa.
Int J Mycobacteriol. 2021 Jan-Mar;10(1):1-7. doi: 10.4103/ijmy.ijmy_4_21.
7
Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic review and meta-analysis.
BMC Med. 2018 Feb 22;16(1):27. doi: 10.1186/s12916-017-1001-7.
8
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.
Cochrane Database Syst Rev. 2022 Apr 26;4(4):CD014877. doi: 10.1002/14651858.CD014877.pub2.
9
Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review.
PLoS One. 2009;4(5):e5561. doi: 10.1371/journal.pone.0005561. Epub 2009 May 15.
10
Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.
Thorax. 2006 Feb;61(2):158-63. doi: 10.1136/thx.2005.045963. Epub 2005 Oct 27.
引用本文的文献
1
Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo.
BMC Infect Dis. 2025 Jul 12;25(1):913. doi: 10.1186/s12879-025-11348-w.
2
Treatment outcomes of multi-drug-resistant and rifampicin-resistant tuberculosis with and without isolation of nontuberculous mycobacteria between 2018-2021: A retrospective cohort study in Ghana.
PLoS Negl Trop Dis. 2025 Jul 2;19(7):e0013204. doi: 10.1371/journal.pntd.0013204. eCollection 2025 Jul.
3
Characterizing Musculoskeletal and Neurological Toxicities Associated With the BPaLM Regimen: A Clinical Evaluation of Arthralgia and Peripheral Neuropathy in Patients With Multidrug-Resistant Tuberculosis (MDR-TB).
Cureus. 2025 Jun 17;17(6):e86248. doi: 10.7759/cureus.86248. eCollection 2025 Jun.
4
Non-communicable diseases and resistant tuberculosis, a growing burden among people living with HIV in Eastern Kenya.
PLOS Glob Public Health. 2025 Jun 20;5(6):e0004212. doi: 10.1371/journal.pgph.0004212. eCollection 2025.
5
Magnitude, predictors, and trends of multidrug-resistant tuberculosis among tuberculosis patients at Debre Markos, Northwest, Ethiopia: a five-year retrospective study.
JAC Antimicrob Resist. 2025 May 27;7(3):dlaf086. doi: 10.1093/jacamr/dlaf086. eCollection 2025 Jun.
6
Rifampicin-resistant unsuccessful results from Xpert® MTB/Rif-Ultra assay in Amhara Region, Ethiopia.
J Clin Tuberc Other Mycobact Dis. 2025 Apr 25;40:100528. doi: 10.1016/j.jctube.2025.100528. eCollection 2025 Aug.
7
Factors associated with tuberculosis drug resistance among presumptive multidrug resistance tuberculosis patients identified in a DRTB surveillance study in western Kenya.
J Clin Tuberc Other Mycobact Dis. 2024 Aug 2;37:100466. doi: 10.1016/j.jctube.2024.100466. eCollection 2024 Dec.
8
Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management.
Curr Opin Pulm Med. 2024 May 1;30(3):217-228. doi: 10.1097/MCP.0000000000001070. Epub 2024 Mar 15.
9
Adverse drug reactions and associated factors in multidrug-resistant tuberculosis: A retrospective review of patient medical records at Mbarara Regional Referral Hospital, Uganda.
SAGE Open Med. 2023 May 3;11:20503121231171350. doi: 10.1177/20503121231171350. eCollection 2023.
10
Incidence and Predictors of Adverse Drug Events Among People Receiving Drug Resistant Tuberculosis Treatment in Uganda: 8-Year Retrospective Cohort Study.
Ther Clin Risk Manag. 2022 Dec 15;18:1117-1127. doi: 10.2147/TCRM.S381800. eCollection 2022.
本文引用的文献
1
Epidemiological Trends of Drug-Resistant Tuberculosis in China From 2007 to 2014: A Retrospective Study.
Medicine (Baltimore). 2016 Apr;95(15):e3336. doi: 10.1097/MD.0000000000003336.
2
Multidrug resistance and demography of newly diagnosed tuberculosis patients in Cross River State, Nigeria.
Int J Mycobacteriol. 2013 Jun;2(2):89-93. doi: 10.1016/j.ijmyco.2013.03.002. Epub 2013 Apr 22.
3
The Prevalence of Tuberculosis in Zambia: Results from the First National TB Prevalence Survey, 2013-2014.
PLoS One. 2016 Jan 15;11(1):e0146392. doi: 10.1371/journal.pone.0146392. eCollection 2016.
4
Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia.
BMC Infect Dis. 2015 Oct 26;15:461. doi: 10.1186/s12879-015-1202-7.
5
Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.
BMC Public Health. 2015 Mar 25;15:291. doi: 10.1186/s12889-015-1614-8.
6
Drug resistance of Mycobacterium tuberculosis in Malawi: a cross-sectional survey.
Bull World Health Organ. 2014 Nov 1;92(11):798-806. doi: 10.2471/BLT.13.126532. Epub 2014 Sep 18.
7
A meta-analysis of drug resistant tuberculosis in Sub-Saharan Africa: how strongly associated with previous treatment and HIV co-infection?
Ethiop J Health Sci. 2013 Nov;23(3):271-82. doi: 10.4314/ejhs.v23i3.10.
8
Drug Resistance among Pulmonary Tuberculosis Patients in Calabar, Nigeria.
Pulm Med. 2013;2013:235190. doi: 10.1155/2013/235190. Epub 2013 Aug 26.
9
Mycobacterial Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in Northern Nigeria.
Tuberc Res Treat. 2013;2013:650561. doi: 10.1155/2013/650561. Epub 2013 Jul 16.
10
Anti-tuberculosis drug resistance among new and previously treated sputum smear-positive tuberculosis patients in Uganda: results of the first national survey.
PLoS One. 2013 Aug 1;8(8):e70763. doi: 10.1371/journal.pone.0070763. Print 2013.
Zotero 插件